» Articles » PMID: 35340523

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis

Overview
Journal Cureus
Date 2022 Mar 28
PMID 35340523
Authors
Affiliations
Soon will be listed here.
Abstract

Euglycemic diabetic keto acidosis (eu-DKA) is a rare but life-threatening metabolic complication associated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy, especially in the setting of extreme physical stress. Due to no apparent hyperglycemia, the significant risk of delayed diagnosis or misdiagnosis exists within patients. Herein, we report a novel case of dapagliflozin-associated eu-DKA with unusual presentation. A 57-year-old female with a six-year history of type 2 diabetes mellitus (DM), for which metformin and dapagliflozin were prescribed, developed severe abdominal pain and signs of acute peritonitis without obvious hyperglycemia after distal pancreatectomy. Based on CT scan and laboratory studies, gastrointestinal tract perforation was suspected but was excluded during laparotomy. Severe metabolic acidosis and strong positive urine ketone indicated diabetic keto acidosis. The patient recovered after active therapy with an intravenous insulin infusion, antibiotics and correction of hypotension, electrolyte imbalance and acidosis. This case provides a new reference for clinicians and surgeons to be concerned with eu-DKA with severe abdominal pain as the main symptom.

Citing Articles

Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports.

Seki H, Ideno S, Shiga T, Watanabe H, Ono M, Motoyasu A J Anesth. 2023; 37(3):465-473.

PMID: 36849747 PMC: 10229478. DOI: 10.1007/s00540-023-03174-8.

References
1.
Sampani E, Sarafidis P, Papagianni A . Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opin Drug Saf. 2020; 19(6):673-682. DOI: 10.1080/14740338.2020.1764532. View

2.
Shah N, Deeb W, Choksi R, Epstein B . Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012; 32(1):80-94. DOI: 10.1002/PHAR.1010. View

3.
Leader R, Cowen J, Rajeev S . Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. BMJ Case Rep. 2019; 12(9). PMC: 6754701. DOI: 10.1136/bcr-2019-231104. View

4.
Dhillon S . Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019; 79(10):1135-1146. PMC: 6879440. DOI: 10.1007/s40265-019-01148-3. View

5.
Clark K, Stoppacher R . Gastric Mucosal Petechial Hemorrhages (Wischnewsky Lesions), Hypothermia, and Diabetic Ketoacidosis. Am J Forensic Med Pathol. 2016; 37(3):165-9. DOI: 10.1097/PAF.0000000000000248. View